SELLAS Life Sciences Group, Inc. (SLS)
NASDAQ: SLS · Real-Time Price · USD
5.35
+0.15 (2.88%)
Mar 20, 2026, 11:44 AM EDT - Market open
SLS Employees
SELLAS Life Sciences Group had 15 employees as of December 31, 2024. The number of employees decreased by 1 or -6.25% compared to the previous year.
Employees
15
Change (1Y)
-1
Growth (1Y)
-6.25%
Revenue / Employee
n/a
Profits / Employee
-$1,790,867
Market Cap
960.77M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 15 | -1 | -6.25% |
| Dec 31, 2023 | 16 | -1 | -5.88% |
| Dec 31, 2022 | 17 | 6 | 54.55% |
| Dec 31, 2021 | 11 | 4 | 57.14% |
| Dec 31, 2020 | 7 | 2 | 40.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Fortrea Holdings | 14,300 |
| Valneva SE | 700 |
| Xeris Biopharma Holdings | 435 |
| Phathom Pharmaceuticals | 371 |
| UroGen Pharma | 291 |
| Xencor | 260 |
| uniQure | 221 |
| Inhibrx Biosciences | 161 |
SLS News
- 19 hours ago - SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 days ago - SELLAS Life Sciences to Present Preclinical Data Highlighting Potent Activity of SLS009 in AML at the 2026 AACR Conference - GlobeNewsWire
- 8 days ago - SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009 - GlobeNewsWire
- 15 days ago - What's Going With SELLAS Life Sciences Stock On Wednesday? - Benzinga
- 2 months ago - SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe - GlobeNewsWire
- 2 months ago - SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - GlobeNewsWire
- 3 months ago - SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025 - GlobeNewsWire
- 5 months ago - SELLAS Life Sciences Group, Inc. (SLS) Discusses Innovation in AML Treatments With Focus on GPS and SLS009 Programs Transcript - Seeking Alpha